Circio: circRNA poster to be presented at the 15th international adenovirus meeting

25 Sep 2023 07:00 CEST

Oslo, Norway, 25 September 2023 - Circio Holding ASA (OSE: CRNA) today announces
that an abstract describing its circular RNA platform has been accepted for
poster presentation at the 15th international adenovirus meeting in Brac Island,
Crotia.

The abstract describes the development of Circio's proprietary circAde vector
system for therapeutic protein expression. The abstract describes the
development of Circio's proprietary circVec vector system for therapeutic
protein expression. Key elements necessary for circRNA biogenesis were
systematically screened and optimized to facilitate high yield circRNA
expression. Additionally, we describe the development of circVac and circAde
vector systems for vaccine and cancer immunotherapy platforms, respectively.
 Here, we show the importance of vector design for durable circRNA expression
and functionality of our viral vector, circAde. Our results highlight the
potential of the circVec platform for the development of novel, more effective
strategies for the treatment of diseases in which durable transgene expression
is desirable.

The poster is scheduled for presentation today, 25 September 2023, and will be
available on Circio's website (https://www.circio.com/en/circvec-platform/)
after the presentation.

Poster circAde, a viral vector system for
title: high and durable protein expression
Date and Monday 25 September 2023, 20:00-
time: 21:30 CEST
Location: Brac Island, Croatia
Abstract 16
number:
Presenter: Eoghan O'Leary, Director RNA
Research

About The International Adenovirus Meeting

The International Adenovirus Meeting is the gathering point for scientists
interested in all aspects of adenovirus infection. Internationally leading
experts will share their ideas and latest results on adenovirus detection in
nature; their clinical impact; their use as therapeutic vaccines and oncolytics;
assembly and lifecycle; and interactions with host proteins, receptors and
cells.

Exchange of ideas and information among scientists working in all fields of
adenovirus biology and applications is fundamental to advancing our ability to
fight against adenovirus-induced disease outbreaks, and to repurpose the virus
as an efficient tool in biomedicine.

The International Adenovirus Meeting is the only conference worldwide focusing
entirely on this particular virus family comprising all aspects of their
biology, pathology and biotechnological applications.

For further information, please contact:
Erik Digman Wiklund, CEO
Phone: +47 413 33 536
Email: erik.wiklund@circio.com (erik.wiklund@targovax.com)

Renate Birkeli, Investor Relations
Phone: +47 922 61 624
Email: renate.birkeli@circio.com (renate.birkeli@targovax.com)

About Circio

Building next generation RNA therapeutics

Circio Holding ASA is a biotechnology company developing novel circular RNA and
immunotherapy medicines.

Circio has established a unique circular RNA (circRNA) platform to develop novel
circRNA medicines for cancer, vaccines, rare disease, protein replacement
therapy and cell therapy. The proprietary circVec technology is based on a
modular genetic cassette design for efficient biogenesis of multifunctional
circRNA that can be deployed for many purposes. The most advanced concept,
circAde, builds on the company´s validated adenovirus platform to deliver
circRNA for durable expression of therapeutic proteins directly into cancer
cells. This unique approach is the only currently known circRNA program capable
of targeting solid tumors. The circVec platform has broad potential
applications, and Circio´s strategy is to generate one or more lead candidates
for in house development in specific disease indications and in parallel seek
partnerships for other technical applications and therapeutic areas. The circRNA
R&D activities are being conducted by the wholly owned subsidiary Circio AB
based at the Karolinska Institute in Stockholm, Sweden.

In addition to Circio's circRNA program, the Company's' clinical stage
immunotherapy programs are designed to activate the patient´s own immune system
to fight cancer cells and provide benefit to patients with no or few treatment
alternatives. ONCOS-102 has demonstrated an excellent safety profile, strong
immune responses and clinical efficacy in several cancer types in Phase 1/2
studies, both as monotherapy and in combinations with checkpoint inhibitors or
standard-of-care chemotherapy. A phase 2 trial to confirm the therapeutic
activity of ONCOS-102 in melanoma patients resistant to PD-1 checkpoint
inhibitor treatment has been designed, and Circio is seeking external financing
and/or partnerships to continue the clinical development.

Circio's second clinical stage program is an immunotherapy targeting KRAS driver
mutations. TG01 has previously shown robust immune responses and encouraging
clinical benefit in surgically resected pancreatic cancer and is currently being
tested in two clinical trials in RAS-mutated pancreatic cancer and multiple
myeloma in the USA and Norway. These studies are being run through academic
collaborative networks, supported by prestigious research grants from Innovation
Norway and the Norwegian Research Council, creating broad future optionality for
the TG01 program at low cost to Circio.

More information:
Access the news on Oslo Bors NewsWeb site